Stoke Therapeutics Inc   (STOK)
Other Ticker:  
Price: $7.6300 $-0.11 -1.421%
Day's High: $8 Week Perf: 14.74 %
Day's Low: $ 7.46 30 Day Perf: 57.64 %
Volume (M): 307 52 Wk High: $ 14.00
Volume (M$): $ 2,344 52 Wk Avg: $6.96
Open: $7.74 52 Wk Low: $3.35

 Market Capitalization (Millions $) 338
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -103
 Cash Flow (TTM) (Millions $) 77
 Capital Exp. (TTM) (Millions $) 2

Stoke Therapeutics Inc
Stoke Therapeutics Inc. is a biotechnology company that is focused on developing innovative therapies for patients with severe genetic diseases, particularly diseases caused by haploinsufficiency. Haploinsufficiency is a genetic condition where a person has only one functioning copy of a gene instead of the normal two, leading to a reduced expression of the gene and potentially causing disease.

Stoke Therapeutics is leveraging its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform to address this issue. The TANGO platform utilizes antisense oligonucleotides to enhance the expression of the non-mutated copy of the gene, increasing the production of the specific protein and potentially treating the underlying disease.

The company aims to develop therapies for a range of genetic disorders, including genetic epilepsies, neurodevelopmental disorders, and other diseases that are not adequately addressed by current treatment options. Stoke Therapeutics is conducting clinical trials and partnering with academic institutions and industry collaborators to accelerate the development and commercialization of its therapies.

Overall, Stoke Therapeutics is at the forefront of developing innovative treatments for severe genetic diseases, using its TANGO platform to enhance gene expression and offer potential therapeutic options for patients in need.

   Company Address: 45 Wiggins Ave Bedford 1730 MA
   Company Phone Number: 430-8200   Stock Exchange / Ticker: NASDAQ STOK
   STOK is expected to report next financial results on March 05, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Stoke Therapeutics Inc

Stoke Therapeutics Inc Sees Impressive Revenue Growth in Third Quarter of 2023 Effort

Stoke Therapeutics Inc, a leading player in the pharmaceutical industry, has shown promising signs of improvement in its financial performance. According to the company's latest financial report for the period ending September 30, 2023, Stoke Therapeutics Inc managed to decrease its loss per share to $-0.55, a significant improvement compared to $-0.63 per share from the previous year. Moreover, the company's earnings per share also saw an upward trend, improving from $-0.69 per share in the preceding quarter.
One of the key highlights of Stoke Therapeutics Inc's recent financial report is the substantial growth in revenue. The company's revenue increased by a remarkable 13.873% to $3.31 million, compared to $2.91 million in the same quarter a year ago. This positive revenue growth comes as a welcome surprise, especially considering that Stoke Therapeutics Inc was able to turn its revenue from negative to positive, from -$2.48 million.

Stoke Therapeutics Inc

Stoke Therapeutics Inc Plunges to 52-Week Low: Reports 10.6% Rise in Loss Per Share Amid Fiscal Period Closing June 2023!

During the past week, Stoke Therapeutics Inc (STOK) experienced a significant drop in its shares, specifically a decrease of -7.58%. This downward movement has further amplified the company's year-to-date performance, which currently stands at -35.64%. What makes this decline particularly noteworthy is that STOK shares have now reached their 52-week low.
To gain a better understanding of these numbers, let's take a closer look at Stoke Therapeutics Inc's fiscal time-frame ending June 30, 2023. During this period, the company reported an increased loss per share of $-0.69. This is in contrast to the same financial reporting period from the previous year, when the loss per share was $-0.63. Prior to that, in the preceding financial reporting period, the company had a loss per share of $-0.53. It is important to note that these figures indicate the loss incurred per share held by investors.

Stoke Therapeutics Inc

Stoke Therapeutics Inc Surges with Record Revenue and Dramatic Reduction in Losses, Ushering in a Promising Future

Stoke Therapeutics Inc has seen an impressive improvement in its financial position, with a substantial revenue elevation in the fiscal three months ending March 31, 2023. The company's revenue increased by a whopping 71.733% to $5.15 million, which supported the cutting of losses to $-0.53 per share, from $-0.66 in the corresponding reporting period a year before.
This is an outstanding achievement for a company that has worked hard to improve its position in the market. In contrast to the Q4 revenue, which surged by 57.602% from $3.27 million, Stoke Therapeutics Inc's Income per Share also improved from $-0.61 per share. This displays the company's steady and reliable growth trajectory.
The fiscal first quarter of 2023 report further revealed that Stoke Therapeutics Inc had reported a net shortfall of $-22.545 million, which was a massive improvement from a deficit of $-24.649 million in the corresponding reporting period a year ago. This impressive demonstration of growth in revenue provides investors with a promising outlook for Stoke Therapeutics Inc?s future performance and investment potential.


Stoke Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com